+ Follow GYNECOLOGIC ONCOLOGY GROUP Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 588820
[Title] => Roche drug helps women with ovarian cancer live longer
[Summary] => Roche recently announced results from a Phase III study of bevacizumab that showed women with previously untreated advanced ovarian cancer who received bevacizumab in combination with chemotherapy, followed by the continuation of bevacizumab alone, had a 39 percent improvement in the likelihood of living longer without the disease worsening (progression-free survival or PFS) compared to chemotherapy alone.
[DatePublished] => 2010-07-01 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
GYNECOLOGIC ONCOLOGY GROUP
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 588820
[Title] => Roche drug helps women with ovarian cancer live longer
[Summary] => Roche recently announced results from a Phase III study of bevacizumab that showed women with previously untreated advanced ovarian cancer who received bevacizumab in combination with chemotherapy, followed by the continuation of bevacizumab alone, had a 39 percent improvement in the likelihood of living longer without the disease worsening (progression-free survival or PFS) compared to chemotherapy alone.
[DatePublished] => 2010-07-01 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
abtest
